STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2004 VERMONT

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT. BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS. BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY. BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a, b} NONDUAL BENEFICIARIES, VERMONT, 2004

			Number of Ber	eficiaries				N	lumber of Ben	efit Months		
Beneficiary						Other/						Other/
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	128,292	374	8,848	50,331	68,664	75	1,202,367	2,852	98,177	426,521	674,105	712
Age												
5 and younger	22,949	0	329	6	22,614	0	217,154	0	3,615	41	213,498	0
6-14	32,869	1	1,280	2	31,586	0	338,204	12	14,534	4	323,654	0
15-20	17,377	0	1,113	2,165	14,092	7	162,805	0	12,483	16,505	133,746	71
21-44	39,825	2	2,821	36,604	365	33	341,333	14	31,211	306,693	3,123	292
45-64	14,754	6	3,226	11,481	6	35	138,508	29	35,495	102,563	72	349
65-74	232	114	64	54	0	0	2,236	1,002	693	541	0	0
75-84	174	141	13	19	1	0	1,414	1,095	133	174	12	0
85 and older	112	110	2	0	0	0	713	700	13	0	0	0
Unknown	0	0	0	0	0	0		0	0	0	0	0
Gender												
Female	69,561	238	4,693	30,673	33,883	74	660,758	1,838	52,437	272,397	333,386	700
Male	58,731	136	4,155	19,658	34,781	1	0 541,609	1,014	45,740	154,124	340,719	12
Unknown	0	0	0	0	0	0		0	0	0	0	0
Race												
White	71,133	184	6,750	33,307	30,856	36	688,081	1,532	75,880	291,094	319,213	362
African American	1,231	4	83	529	615	0	0 10,498	22	847	4,018	5,611	0
Other/unknown	55,928	186	2,015	16,495	37,193	39	503,788	1,298	21,450	131,409	349,281	350
Use of Nursing Facilities ^c												
Entire year	86	36	50	0	0	0	838	335	503	0	0	0
Part year	125	12	93	19	0	1	1,289	108	970	199	0	12
None	128,081	326	8,705	50,312	68,664	74	1,200,240	2,409	96,704	426,322	674,105	700
Maintenance Assistance Status												
Cash	20,586	35	7,530	4,202	8,819	0	216,190	354	85,317	40,916	89,603	0
Medically needy	8,186	117	551	5,257	2,261	0	72,273	1,112	4,984	48,179	17,998	0
Poverty-related	49,896	0	0	2,509	47,312	75	478,900	0	0	17,848	460,340	712
Other/unknown	49,624	222	767	38,363	10,272	0	435,004	1,386	7,876	319,578	106,164	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	128,292	374	8,848	50,331	68,664	75	1,202,367	2,852	98,177	426,521	674,105	712
FFS part year, with Rx claims	0	0	0	0	0	0		0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0		0	0	0	0	0

0

0

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3 ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{9, b} NONDUAL BENEFICIARIES, VERMONT, 2004

Beneficiary	Dancartana with at	Mean Number			Mean \$, All Medicaid	Rx \$ as a Percentage of All Medicaid	Number of
Characteristics	Percentage with at Least One Rx	of Rx	Mean Rx \$	\$ per Rx	FFS \$°	FFS \$ ^d	Beneficiaries
All	66.6 %	8.7	\$555	\$64	\$3,487	15.9 %	128,292
Age							
5 and younger	66.6	3.3	152	46	1,928	7.9	22,949
6-14	60.2	4.4	307	70	3,285	9.3	32,869
15-20	65.2	6.3	423	67	4,703	9.0	17,377
21-44	69.1	10.7	653	61	3,271	20.0	39,825
45-64	75.9	23.7	1,588	67	5,362	29.6	14,754
65-74	68.5	32.2	1,778	55	7,601	23.4	232
75-84	62.1	29.6	1,805	61	7,676	23.5	174
85 and older	48.2	22.9	1,218	53	8,239	14.8	112
Unknown	0.0	0.0	0	0	0	0.0	0
Basis of Eligibility ^e							
Aged	57.2	28.0	1,559	56	8,171	19.1	374
Disabled	86.3	35.5	2,860	81	17,330	16.5	8,848
Adults	68.6	10.4	591	57	2,483	23.8	50,331
Children	62.6	4.0	224	56	2,406	9.3	68,664
Unknown	77.3	14.4	2,792	193	10,220	27.3	75
Gender							
Female	71.3	10.3	609	59	3,367	18.1	69,561
Male	61.0	6.9	491	71	3,629	13.5	58,731
Unknown	0.0	0.0	0	0	0	0.0	0
Race							
White	72.6	11.7	747	64	4,307	17.3	71,133
African American	58.3	6.1	429	70	3,154	13.6	1,231
Other/unknown	59.1	5.1	315	62	2,451	12.8	55,928
Use of Nursing							
Facilities ^f							
Entire year	100.0	85.6	6,336	74	52,762	12.0	86
Part year	99.2	81.3	5,152	63	49,979	10.3	125
None	66.5	8.6	547	63	3,409	16.0	128,081
Maintenance Assistance Status							
Cash	78.3	18.7	1,376	74	8,219	16.7	20,586
Medically needy	70.0	10.9	649	59	3,256	19.9	8,186
Poverty related	60.8	3.4	180	53	1,637	11.0	49,896
Other/unknown	67.0	9.6	577	60	3,423	16.9	49,624

Table ND3 Nondual Beneficiaries

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving fost care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4 ${\tt MEDICAID\ PHARMACY\ BENEFIT\ USE\ AND\ REIMBURSEMENT\ PER\ BENEFIT\ MONTH,\ BY\ BENEFICIARY\ CHARACTERISTIC}^{a,\,b}$ NONDUAL BENEFICIARIES, VERMONT, 2004

					N	umber of Rx, Per	centage with:			_	Numb	er
Beneficiary Characteristics	Mean Number of Rx	A Mean Rx \$	Rx \$ as a centage of II Medicaid FFS \$°	None	0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than	Mean \$, All Medicaid FFS \$ ^d	Beneficiaries	Benefit Months
All	0.9	\$59	15.9 %	33.4 %	49.6 %	7.2 %	7.1 %	2.2 %	0.5 %	\$372	128,292	1,202,367
Age												
5 and younger	0.3	16	7.9	33.4	63.2	2.5	8.0	0.0	0.0	204	22,949	217,154
6-14	0.4	30	9.3	39.8	52.9	4.2	2.8	0.2	0.0	319	32,869	338,204
15-20	0.7	45	9.0	34.8	52.5	7.1	4.8	0.7	0.0	502	17,377	162,805
21-44	1.3	76	20.0	30.9	45.5	10.4	10.0	2.7	0.5	382	39,825	341,333
45-64	2.5	169	29.6	24.1	30.2	12.7	20.5	10.0	2.4	571	14,754	138,508
65-74	3.3	185	23.4	31.5	18.5	7.8	23.3	12.9	6.0	789	232	2,236
75-84	3.6	222	23.5	37.9	13.8	8.0	19.5	16.1	4.6	945	174	1,414
85 and older	3.6	191	14.8	51.8	7.1	1.8	19.6	16.1	3.6	1,294	112	713
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Basis of Eligibility ^e												
Aged	3.7	205	19.1	42.8	10.7	4.5	22.7	14.4	4.8	1,072	374	2,852
Disabled	3.2	258	16.5	13.7	29.2	13.1	25.0	14.3	4.7	1,562	8,848	98,177
Adults	1.2	70	23.8	31.4	44.0	10.8	10.7	2.7	0.3	293	50,331	426,521
Children	0.4	23	9.3	37.4	56.6	3.8	2.0	0.2	0.0	245	68,664	674,105
Unknown	1.5	294	27.3	22.7	45.3	16.0	12.0	2.7	1.3	1,077	75	712
Gender												
Female	1.1	64	18.1	28.7	51.6	8.2	8.0	2.8	0.6	355	69,561	660,758
Male	0.7	53	13.5	39.0	47.3	6.0	6.0	1.5	0.3	394	58,731	541,609
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Race												
White	1.2	77	17.3	27.4	50.0	8.9	9.6	3.3	8.0	445	71,133	688,081
African American	0.7	50	13.6	41.7	46.3	5.2	5.4	1.3	0.1	370	1,231	10,498
Other/unknown	0.6	35	12.8	40.9	49.2	5.1	3.9	0.8	0.1	272	55,928	503,788
Use of Nursing Facilities ^f												
Entire year	8.8	650	12.0	0.0	3.5	5.8	18.6	36.0	36.0	5,415	86	838
Part year	7.9	500	10.3	0.8	7.2	7.2	28.0	27.2	29.6	4,847	125	1,289
None	0.9	58	16.0	33.5	49.7	7.2	7.0	2.2	0.4	364	128,081	1,200,240
Maintenance Assistance Status												
Cash	1.8	131	16.7	21.7	47.3	9.4	13.6	6.1	1.9	783	20,586	216,190
Medically needy	1.2	74	19.9	30.0	46.9	9.9	9.8	3.0	0.5	369	8,186	72,273
Poverty related	0.4	19	11.0	39.2	56.0	3.3	1.4	0.1	0.0	171	49,896	478,900
Other/unknown	1.1	66	16.9	33.0	44.7	9.8	9.6	2.6	0.3	391	49,624	435,004

Table ND4 Nondual Beneficiaries

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5

AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{6, b, c}

NONDUAL BENEFICIARIES, VERMONT, 2004

Beneficiary		All Rx		Patented Br	and-Name	Drugs	Off-Patent B	Brand-Name	Drugs	Gen	eric Drugs	
·	Number			Number			Number			Number		
Beneficiary Characteristics	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx
All	0.9	\$59	\$64	0.4	\$44	\$121	0.1	\$5	\$85	0.5	\$11	\$21
Age												
5 and younger	0.3	16	46	0.1	12	113	0.0	1	40	0.2	3	14
6-14	0.4	30	70	0.2	25	110	0.0	1	76	0.2	4	20
15-20	0.7	45	67	0.3	35	115	0.0	3	77	0.3	7	22
21-44	1.3	76	61	0.4	54	123	0.1	7	90	0.7	15	21
45-64	2.5	169	67	1.0	125	128	0.1	13	95	1.4	31	22
65-74	3.3	185	55	1.4	144	102	0.1	7	55	1.8	33	19
75-84	3.6	222	61	1.5	174	117	0.1	6	56	2.0	43	21
85 and older	3.6	191	53	1.5	149	99	0.2	7	40	1.9	35	18
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Basis of Eligibility ^d												
Aged	3.7	205	56	1.5	158	108	0.1	6	46	2.1	40	20
Disabled	3.2	258	81	1.3	199	150	0.2	21	102	1.7	38	23
Adults	1.2	70	57	0.4	49	113	0.1	6	84	0.7	15	20
Children	0.4	23	56	0.2	18	100	0.0	1	62	0.2	4	18
Unknown	1.5	294	193	0.5	265	496	0.1	11	152	0.9	18	19
Gender												
Female	1.1	64	59	0.4	46	114	0.1	5	78	0.6	12	20
Male	0.7	53	71	0.3	41	132	0.0	4	99	0.4	8	21
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Race												
White	1.2	77	64	0.5	57	123	0.1	6	89	0.7	14	21
African American	0.7	50	70	0.3	39	142	0.0	4	110	0.4	8	19
Other/unknown	0.6	35	62	0.2	27	114	0.0	2	70	0.3	6	20
Use of Nursing Facilities ^e												
Entire year	8.8	650	74	3.5	522	150	0.4	34	76	4.8	94	19
Part year	7.9	500	63	2.7	367	134	0.5	34	68	4.6	97	21
None	0.9	58	63	0.4	43	120	0.1	5	85	0.5	10	21
Maintenance Assistance												
Status	4.0	404	7.4	0.7	400	4.44	0.4	4.4	400	4.0	0.4	04
Cash	1.8	131	74 50	0.7	100	141	0.1	11	100	1.0	21	21
Medically needy	1.2	74 10	59 53	0.5	52	115	0.1	7	85 50	0.7	15	21
Poverty related	0.4	19	53	0.1	14	97	0.0	1	59	0.2	3	18
Other/unknown	1.1	66	60	0.4	48	114	0.1	5	79	0.6	13	21

Table ND5 Nondual Beneficiaries

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Vermont, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}

NONDUAL BENEFICIARIES, VERMONT, 2004

		er of Rx	•		\$ per Benefit Month Among Users Φ Φ					\$ pe	r Rx			_		Users ^e	
Therapeutic Category	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.2	0.1	0.0	0.1	\$11	\$8	\$1	\$3	\$51	\$119	\$65	\$20	118,229	\$6,056,816	49,927	38.9 %	530,160
Biologicals	0.2	0.2	0.0	0.0	145	134	0	11	662	640	17	1,283	1,663	1,101,733	766	0.6	7,624
Antineoplastic Agents	0.5	0.1	0.0	0.4	135	114	5	16	257	851	210	43	2,779	713,678	500	0.4	5,300
Endocrine/Metabolic Drugs	0.5	0.2	0.1	0.3	26	17	3	7	51	97	37	25	107,278	5,517,455	20,211	15.8	209,943
Cardiovascular Agents	1.0	0.4	0.0	0.6	44	35	1	9	45	92	38	15	117,814	5,303,883	11,518	9.0	119,583
Respiratory Agents	0.4	0.3	0.0	0.2	26	23	0	2	61	88	44	16	119,464	7,257,488	26,308	20.5	281,719
Gastrointestinal Agents	0.5	0.2	0.0	0.2	40	32	3	5	87	136	121	24	53,554	4,676,784	11,044	8.6	116,618
Genitourinary Agents	0.2	0.1	0.0	0.1	13	11	1	1	59	88	44	19	11,274	667,525	4,641	3.6	49,793
CNS Drugs	0.9	0.4	0.1	0.4	70	52	7	11	81	136	101	27	214,642	17,465,313	24,280	18.9	249,764
Stimulants/Anti-obesity/Anorexia Miscellaneous Psychological/	0.8	0.6	0.0	0.1	66	60	1	5	87	99	76	37	46,151	4,026,999	5,607	4.4	61,019
Neurological Agents	0.2	0.1	0.0	0.1	57	50	1	6	283	452	120	71	3,219	912,210	1,496	1.2	15,933
Analgesics and Anesthetics	0.6	0.1	0.0	0.4	24	16	1	7	44	148	196	16	160,124	7,003,938	28,059	21.9	289,250
Neuromuscular Agents	0.6	0.2	0.1	0.3	49	30	13	6	83	152	142	20	69,595	5,744,792	11,216	8.7	117,346
Nutritional Products	0.2	0.0	0.0	0.2	2	0	0	2	13	36	15	12	20,842	261,234	10,102	7.9	108,953
Hematological Agents	0.6	0.2	0.1	0.3	98	89	3	6	169	513	47	18	9,409	1,592,987	1,570	1.2	16,332
Topical Products	0.2	0.1	0.0	0.1	8	5	0	3	40	85	52	20	59,401	2,404,483	27,986	21.8	300,138
Miscellaneous Products	0.1	0.1	0.0	0.0	12	9	1	2	89	86	194	83	5,097	455,487	3,427	2.7	37,692
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	9	0	0	0	40	0	0	0	1,594	64,338	635	0.5	6,901
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	1,122,129	71,227,143	n.a.	n.a.	n.a.

- a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Vermont, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}

NONDUAL BENEFICIARIES, VERMONT, 2004

			Users		Ar	mong Users	
Top 10 Drug Groups	Total Medicaid Rx \$	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	Rx \$ per Rx	\$ per Benefit Month
ANTIDEPRESSANTS	\$8,645,825	25,550	19.9 %	266,737	0.5	\$67	\$32
ANTIPSYCHOTICS	7,667,329	6,625	5.2	72,109	0.6	181	106
ANTICONVULSANT	5,247,165	7,611	5.9	81,281	0.6	104	65
ANTIASTHMATIC	4,499,646	24,405	19.0	264,038	0.3	63	17
ANALGESICS - Narcotic	4,204,985	32,139	25.1	336,433	0.3	38	12
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	4,026,999	6,805	5.3	74,743	0.6	87	54
ULCER DRUGS	3,686,985	9,980	7.8	105,819	0.4	87	35
ANTIHYPERLIPIDEMIC	2,837,375	4,383	3.4	46,823	0.6	109	61
ANTIVIRAL	2,192,987	1,890	1.5	19,848	0.3	335	110
ANTIDIABETIC	2,132,997	4,181	3.3	44,251	0.7	71	48
Total	45,142,293	123,569		1,312,082	n.a.	n.a.	n.a.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, VERMONT, 2004

	All Top 10 Dru	g Groups		ANTIDE	PRESSANTS				ANTIPS	SYCHOTICS		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month
All	554,748	\$45,142,293	25,550	19.9 %	266,737	0.5	\$32	6,625	5.2 %	72,109	0.6	\$106
Female	336,656	25,814,340	17,824	25.6	187,780	0.5	33	3,585	5.2	39,409	0.6	95
Disabled	111,860	10,405,893	3,509	74.8	40,481	0.6	42	1,544	32.9	17,855	0.7	133
E and variages	606	46,404	2	1.5	23	0.7	16	4	3.0	47	0.3	18
5 and younger	4,250	406,742	98	22.6	1,149	0.6	29	94	21.7	1,082	0.7	111
6-14	5,212	489,519	206	49.9	2,394	0.6	35	123	29.8	1,450	0.6	107
15-20	38,644	3,693,400	1,445	87.0	16,604	0.5	40	669	40.3	7,700	0.7	119
21-44	62,035	5,691,933	1,736	86.7	20,069	0.7	45	651	32.5	7,547	0.8	157
45-64	1,043	64,349	20	50.0	218	0.7	35	3	7.5	29	2.8	250
65-74	70	13,546	2	25.0	24	0.3	19	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	224,796	15,408,447	14,315	22.1	147,299	0.4	31	2,041	3.1	21,554	0.4	63
_	5,082	301,981	9	0.1	98	0.2	4	13	0.1	154	0.3	43
5 and younger	21,269	1,598,962	712	4.6	7,991	0.5	24	254	1.6	2,900	0.6	95
6-14	21,683	1,436,770	1,814	21.4	19,076	0.4	24	364	4.3	3,986	0.5	70
15-20	119,789	7,769,347	8,890	38.1	90,782	0.4	30	1,111	4.8	11,468	0.3	49
21-44	54,546	4,104,480	2,844	45.7	28,853	0.6	38	285	4.6	2,909	0.5	69
45-64	881	67,460	15	16.5	166	0.8	44	4	4.4	38	0.5	116
65-74	981	76,750	17	16.0	186	0.7	33	4	3.8	40	0.9	135
75-84	565	52,697	14	18.7	147	0.8	52	6	8.0	59	1.0	221
85 and older		•		_								
Male	218,092	19,327,953	7,726	13.2	78,957	0.5	31	3,040	5.2	32,700	0.6	120
Disabled	65,532	7,054,237	1,702	41.0	19,561	0.6	37	1,234	29.7	14,084	0.8	154
E and vounder	958	86,006	12	6.2	136	0.5	15	10	5.2	111	0.5	108
5 and younger 6-14	10,493	1,128,866	248	29.3	2,920	0.6	32	299	35.3	3,483	0.7	127
	7,874	848,077	248	35.4	2,915	0.6	38	221	31.6	2,563	0.7	137
15-20	18,966	2,121,006	561	48.3	6,338	0.6	39	417	35.9	4,682	8.0	168
21-44	26,677	2,809,913	627	51.2	7,180	0.6	39	281	23.0	3,173	0.8	180
45-64	503	55,316	5	20.8	60	0.4	13	6	25.0	72	0.8	211
65-74	61	5,053	1	20.0	12	0.1	2	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	152,560	12,273,716	6,024	11.0	59,396	0.5	29	1,806	3.3	18,616	0.5	95
_	8,321	526,137	32	0.3	375	0.3	10	25	0.2	272	0.3	41
5 and younger	41,139	3,384,942	1,045	6.5	11,743	0.5	28	604	3.8	6,937	0.6	103
6-14	18,721	1,518,822	950	12.2	10,049	0.5	29	380	4.9	4,034	0.5	99
15-20	49,600	3,860,538	2,677	19.6	24,614	0.4	28	610	4.5	5,578	0.4	86
21-44	33,104	2,866,241	1,280	24.1	12,222	0.5	33	163	3.1	1,552	0.6	90
45-64	704	50,397	17	22.1	181	0.8	44	12	15.6	123	0.3	51
65-74	681	46,745	12	21.8	128	0.6	28	5	9.1	57	1.1	134
75-84	290	19,894	11	31.4	84	1.1	64	7	20.0	63	0.4	37
85 and older												
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7A **Nondual Beneficiaries**

- a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7A Nondual Beneficiaries

TABLE ND.7B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}

NONDUAL BENEFICIARIES, VERMONT, 2004

		ANTICO	ONVULSANT				ANTIA	STHMATIC				ANALGES	SICS - Narcoti	С	
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per
All	7,611	5.9 %	81,281	0.6	\$65	24,405	19.0 %	264,038	0.3	\$17	32,139	25.1 %	336,433	0.3	\$13
Female	4,877	7.0	52,708	0.6	61	14,277	20.5	155,191	0.3	17	20,978	30.2	224,642	0.3	11
Disabled	1,808	38.5	20,904	0.8	85	2,452	52.2	28,537	0.4	28	3,390	72.2	39,216	0.5	25
	26	19.3	308	0.7	75	53	39.3	600	0.3	21	11	8.1	129	0.1	1
5 and younger	105	24.2	1,176	0.9	109	131	30.2	1,539	0.3	16	50	11.5	588	0.1	2
6-14	115	27.8	1,349	0.9	102	125	30.3	1,477	0.3	18	137	33.2	1,595	0.2	2
15-20	793	47.8	9,172	0.7	87	810	48.8	9,450	0.3	20	1,517	91.4	17,544	0.5	21
21-44	759	37.9	8,818	0.8	78	1,303	65.1	15,156	0.4	34	1,650	82.4	19,087	0.5	30
45-64	9	22.5	73	1.7	63	30	75.0	315	0.7	54	22	55.0	241	0.2	6
65-74	1	12.5	8	1.0	562	0	0.0	0	0.0	0	3	37.5	32	0.4	128
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	3,069	4.7	31,804	0.5	45	11,825	18.2	126,654	0.3	15	17,588	27.1	185,426	0.3	8
_	25	0.2	265	0.4	68	1,801	16.5	19,864	0.2	12	272	2.5	3,049	0.1	1
5 and younger	174	1.1	1,917	0.6	77	2,531	16.2	28,224	0.2	12	733	4.7	8,344	0.1	1
6-14	243	2.9	2,541	0.4	49	1,605	18.9	16,948	0.2	10	2,334	27.5	24,608	0.2	2
15-20	1,987	8.5	20,573	0.5	39	4,369	18.7	45,613	0.3	16	11,758	50.4	123,597	0.3	9
21-44	624	10.0	6,337	0.6	52	1,462	23.5	15,362	0.4	28	2,434	39.1	25,220	0.3	11
45-64 65-74	3	3.3	36	0.7	35	35	38.5	409	0.4	39	20	22.0	218	0.4	13
75-84	9	8.5	89	0.7	47	16	15.1	174	0.5	52	27	25.5	306	0.3	7
	4	5.3	46	0.6	66	6	8.0	60	0.6	47	10	13.3	84	0.5	42
85 and older Male	2,734	4.7	28,573	0.7	71	10,128	17.2	108,847	0.3	17	11,161	19.0	111,791	0.3	17
	1,028	24.7	11,744	0.8	91	1.104	26.6	12,663	0.4	27	1,578	38.0	17,775	0.5	36
Disabled	20	10.3	221	0.6	95	1,104	62.4	1,426	0.4	25	1,576	9.8	217	0.1	1
5 and younger	155	18.3	1,810	0.7	93 91	192	22.7	2,247	0.3	18	58	6.9	676	0.1	1
6-14	140	20.0	1,631	0.7	114	114	16.3	1,332	0.3	12	150	21.4	1,759	0.1	2
15-20	371	32.0	4,241	0.8	99	218	18.8	2.483	0.3	23	580	50.0	6,508	0.2	28
21-44	338	27.6	3,793	0.7	74	446	36.4	5,019	0.5	35	759	62.0	8,495	0.6	53
45-64	4	16.7	48	0.4	58	12	50.4	144	0.9	88	12	50.0	120	0.5	43
65-74	0	0.0	0	0.0	0	1	20.0	12	0.9	17	0	0.0	0	0.0	43
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	1,706	3.1	16,829	0.6	57	9,024	16.5	96,184	0.3	15	9,583	17.6	94,016	0.3	13
Other Eligibles	61	0.5	688	0.5	53	2,677	22.9	29,161	0.2	13	372	3.2	4,143	0.1	1
5 and younger	229	1.4	2,553	0.6	76	3,292	20.6	36,695	0.2	14	784	4.9	8,858	0.1	1
6-14	168	2.2	1,729	0.6	60	1,048	13.5	10,969	0.2	13	1,382	17.8	14,262	0.1	2
15-20	806	5.9	7,580	0.5	55	1,238	9.1	11,740	0.3	18	5,247	38.4	48,886	0.1	17
21-44	428	8.1	4,139	0.6	49	723	13.6	7,149	0.4	34	1,752	33.0	17,360	0.4	18
45-64	7	9.1	80	1.1	66	19	24.7	182	0.3	24	1,732	19.5	166	0.4	3
65-74	5	9.1	56	0.5	66	21	38.2	224	0.5	35	23	41.8	261	0.3	6
75-84	2	5.7	4	1.0	45	6	17.1	64	0.3	15	8	22.9	80	0.3	2
85 and older															
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7B

- a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7B Nondual Beneficiaries

TABLE ND.7C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
NONDUAL BENEFICIARIES, VERMONT, 2004

	STIMULA	NTS/ANTI-	OBESITY/AN	OREXIAN	TS		ULCE	R DRUGS				ANTIHYP	PERLIPIDEMI	0	
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Rx \$ per Benefit
All	6,805	5.3 %	74,743	0.6	\$54	9,980	7.8 %	105,819	0.4	\$35	4,383	3.4 %	46,823	0.6	\$61
Female	2,220	3.2	24,524	0.6	51	6,537	9.4	70,684	0.4	35	2,475	3.6	26,934	0.6	61
Disabled	371	7.9	4,338	0.6	59	1,794	38.2	20,777	0.5	48	895	19.1	10,446	0.6	67
5 and younger	5	3.7	51	0.5	27	20	14.8	228	0.6	35	0	0.0	0	0.0	0
6-14	123	28.3	1,443	0.7	60	36	8.3	422	0.4	25	1	0.2	12	0.3	13
15-20	71	17.2	842	0.7	62	61	14.8	718	0.4	25	1	0.2	12	0.1	6
21-44	103	6.2	1,223	0.6	54	578	34.8	6,671	0.5	42	146	8.8	1,717	0.6	63
45-64	68	3.4	767	0.6	65	1,081	54.0	12,544	0.6	54	733	36.6	8,541	0.6	68
65-74	1	2.5	12	0.3	23	17	42.5	186	0.8	52	11	27.5	132	0.8	79
75-84	0	0.0	0	0.0	0	1	12.5	8	1.0	102	3	37.5	32	0.7	87
	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	1,849	2.9	20,186	0.6	50	4,743	7.3	49,907	0.3	29	1,580	2.4	16,488	0.5	57
5 and younger	27	0.2	301	0.4	31	195	1.8	1,869	0.3	14	9	0.1	68	0.1	2
6-14	950	6.1	10,652	0.6	51	264	1.7	2,977	0.2	16	4	0.0	47	0.4	35
15-20	323	3.8	3,488	0.6	52	427	5.0	4,506	0.2	13	9	0.1	78	0.3	33
21-44	439	1.9	4,628	0.4	45	2,516	10.8	26,560	0.3	27	448	1.9	4,631	0.4	48
45-64	109	1.8	1,105	0.5	51	1,270	20.4	13,249	0.5	44	1,052	16.9	11,008	0.5	60
65-74	0	0.0	0	0.0	0	22	24.2	239	0.6	41	24	26.4	265	0.6	67
75-84	0	0.9 0.0	12 0	0.3	5 0	30 19	28.3 25.3	321 186	0.7 0.8	51 66	25 9	23.6 12.0	285 106	0.7 0.8	88 87
85 and older	U	0.0	U	0.0	U	19	25.5	100	0.6	00	9	12.0	106	0.6	01
Male	4,585	7.8	50,219	0.6	55	3,443	5.9	35,135	0.4	35	1,908	3.2	19,889	0.6	60
Disabled	709	17.1	8,209	0.8	70	833	20.0	9,410	0.5	45	503	12.1	5,804	0.7	69
	7	3.6	76	0.9	89	25	12.9	293	0.5	29	1	0.5	12	0.3	10
5 and younger	438	51.8	5,071	0.8	70	39	4.6	466	0.5	36	1	0.1	12	0.8	64
6-14	193	27.6	2,251	0.8	67	52	7.4	608	0.4	31	2	0.3	24	0.1	6
15-20	45	3.9	508	0.7	64	256	22.0	2,877	0.5	39	106	9.1	1,217	0.6	58
21-44 45-64	26	2.1	303	0.6	81	450	36.8	5,044	0.6	51	380	31.0	4,383	0.7	72
45-64 65-74	0	0.0	0	0.0	0	9	37.5	98	0.4	59	10	41.7	120	0.8	74
75-84	0	0.0	0	0.0	0	2	40.0	24	0.9	57	3	60.0	36	0.6	90
	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	3,876	7.1	42,010	0.6	52	2,610	4.8	25,725	0.4	31	1,405	2.6	14,085	0.5	56
5 and younger	117	1.0	1,317	0.4	28	276	2.4	2,548	0.3	17	13	0.1	142	0.1	2
6-14	2,638	16.5	29,192	0.6	53	212	1.3	2,451	0.3	18	3	0.0	35	0.1	6
15-20	798	10.3	8,485	0.6	55	229	2.9	2,298	0.3	18	8	0.1	86	0.3	21
21-44	257	1.9	2,389	0.6	47	1,132	8.3	10,826	0.4	33	434	3.2	4,362	0.5	51
45-64	64	1.2	604	0.6	67	711	13.4	7,086	0.5	43	917	17.3	9,138	0.6	60
65-74	0	0.0	0	0.0	0	21	27.3	222	0.5	35	17	22.1	176	0.6	70
75-84	1	1.8	11	0.4	5	20	36.4	201	0.5	31	10	18.2	120	8.0	87
85 and older	1	2.9	12	0.2	2	9	25.7	93	0.8	79	3	8.6	26	0.4	43
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7C Nondual Beneficiaries

- a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7C Nondual Beneficiaries

TABLE ND.7D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, VERMONT, 2004

		AN ⁻	TIVIRAL				ANTI	DIABETIC				
Beneficiary Characteristics	Number of Users 1,890	Users as % of All Benes 1.5 %	Number of Benefit Months Among Users 19,848	of Rx	Mean Rx \$ per Benefit Month	Number of Users 4,181	Users as % of All Benes 3.3 %	Number of Benefit Months Among Users 44,251	of Rx	Mean Rx \$ per Benefit Month \$48	Number of Beneficiaries 128,292	Number of Benefit Months 1,202,367
Female	1,384	2.0	14,659	0.3	67	2,589	3.7	27,833	0.7	47	69,561	660,758
Disabled	214	4.6	2,479	0.4	128	950	20.2	10,975	0.7	49	4,693	52,437
Disabled	1	0.7	12	0.6	28	0	0.0	0	0.0	0	135	1,475
5 and younger	6	1.4	70	0.7	26	3	0.7	36	0.7	56	434	4,915
6-14	10	2.4	116	0.1	10	22	5.3	259	0.6	53	413	4,629
15-20	111	6.7	1,304	0.3	134	237	14.3	2,762	0.6	45	1,660	18,533
21-44	85	4.2	976	0.4	142	669	33.4	7,697	0.7	50	2,002	22,384
45-64	1	2.5	1	1.0	27	18	45.0	209	0.8	29	40	427
65-74	0	0.0	0	0.0	0	1	12.5	12	0.9	75	8	73
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	1
85 and older Other Eligibles	1,170	1.8	12,180	0.3	55	1,639	2.5	16,858	0.7	46	64,868	608,321
Other Eligibles	26	0.2	284	0.3	8	9	0.1	91	0.6	54	10,917	103,153
5 and younger	71	0.2	799	0.2	8	60	0.1	658	0.6	61	15,614	159,860
6-14	129			0.1	40	89		910	0.7	61	*	•
15-20		1.5	1,408	0.2	40 60		1.0 2.9		0.7		8,492	78,881
21-44	756	3.2	7,780			675		6,890		44	23,348	206,902
45-64	185 0	3.0	1,892 0	0.3	73 0	764 17	12.3	7,857	0.7	46 47	6,225	57,331
65-74		0.0		0.0			18.7	173	0.7		91	891
75-84	1	0.9	12	0.2	4	20	18.9	225	0.7	36	106	828
85 and older	2	2.7	5	0.6	28	5	6.7	54	0.7	21	75	475
Male	506	0.9	5,189	0.5	232	1,592	2.7	16,418	0.7	50	58,731	541,609
Disabled	136	3.3	1,536	0.5	273	461	11.1	5,170	0.7	55	4,155	45,740
	1	0.5	12	0.5	24	0	0.0	0	0.0	0	194	2,140
5 and younger	5	0.6	54	0.1	5	18	2.1	214	0.6	60	846	9,619
6-14	13	1.9	154	0.2	41	10	1.4	120	0.6	54	700	7,854
15-20	55	4.7	613	0.6	274	88	7.6	1,014	0.7	48	1,161	12,678
21-44	62	5.1	703	0.5	348	337	27.5	3,726	0.8	56	1,224	13,111
45-64	0	0.0	0	0.0	0	6	25.0	72	1.0	57	24	266
65-74	0	0.0	0	0.0	0	2	40.0	24	0.6	9	5	60
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	12
85 and older Other Eligibles	370	0.7	3,653	0.4	215	1,131	2.1	11,248	0.7	48	54,576	495,869
Other Eligibles	26	0.7	284	0.4	9	1,131	0.1	150	1.0	107	11,703	110,386
5 and younger			_		9 27						,	,
6-14	34	0.2	368	0.3		58	0.4	636	0.8	67	15,975	163,810
15-20	28 175	0.4	303	0.2	10 224	45 259	0.6	424	0.8	98 50	7,772	71,441
21-44	175	1.3	1,577	0.5		358	2.6	3,456	0.7	50 40	13,656	103,220
45-64	100	1.9	1,050	0.6	398	626	11.8	6,255	0.7	40	5,303	45,682
65-74	3	3.9	30	0.1	3	16	20.8	166	0.8	36	77	652
75-84	3	5.5	29	0.1	5	10	18.2	112	1.0	49	55	453
85 and older	1	2.9	12	0.1	1	5	14.3	49	0.8	48	35	225
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Table ND7D Nondual Beneficiaries

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC^{a, b}

NONDUAL BENEFICIARIES, VERMONT, 2004

Beneficiary Characteristics	Rx \$ per Benefit Month	Number of Rx per Benefit Month	Number of All-Year Nursing Facility Residents	Benefit Months Among All- Year Nursing Facility Residents
All	\$650	8.8	86	838
Age	·			
0-64	840	10.0	49	498
65-74	554	11.0	8	66
75-84	289	6.2	12	129
85 and older	362	6.0	17	145
Unknown	0	0.0	0	0
Gender				
Female	617	8.6	59	604
Male	737	9.3	27	234
Unknown	0	0.0	0	0
Race				
White	709	9.1	70	699
African American	0	0	0	0
Other/unknown	353	7.2	16	139
Basis of Eligibility ^c				
Aged	360	6.9	36	335
Disabled	843	10.0	50	503
Adults	0	0.0	0	0
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2004 file for Vermont, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2004 Medicaid enrollment. A total of 125 beneficiaries who were in nursing facilities for part of their enrollment and their 1,289 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

TABLE ND.9 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BRAND STATUS AND THERAPEUTIC CATEGORY NONDUAL BENEFICIARIES, VERMONT, 2004

		er of Rx	•			er Bene Among		th		\$ per				_		Users	
Therapeutic Category	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total Number of Rx	Total Rx \$	P Number of Users	As a dercentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.7	0.3	0.1	0.4	\$32	\$21	\$3	\$9	\$44	\$77	\$50	\$22	464	\$20,364	66	76.7 %	632
Biologicals	0.1	0.0	0.0	0.1	4	0	0	4	27	0	0	27	5	136	5	5.8	36
Antineoplastic Agents	1.2	0.8	0.0	0.4	224	175	0	48	187	219	0	121	18	3,358	2	2.3	15
Endocrine/Metabolic Drugs	1.3	0.6	0.1	0.6	80	69	3	8	62	118	27	14	536	33,192	42	48.8	414
Cardiovascular Agents	1.7	0.4	0.0	1.3	47	31	1	16	27	76	25	12	914	25,086	55	64.0	532
Respiratory Agents	8.0	0.6	0.0	0.2	60	56	1	3	73	89	30	19	343	24,949	42	48.8	416
Gastrointestinal Agents	1.2	0.5	0.1	0.7	69	52	5	12	57	106	90	18	618	35,229	56	65.1	510
Genitourinary Agents	0.9	0.5	0.1	0.3	48	36	5	7	56	75	68	24	234	13,014	26	30.2	270
CNS Drugs	2.2	1.2	0.1	1.0	245	221	6	19	110	191	84	19	1,589	174,712	71	82.6	713
Stimulants/Anti-obesity/Anorexia Miscellaneous Psychological/	0.3	0.0	0.0	0.3	5	0	0	5	16	0	0	16	7	112	2	2.3	23
Neurological Agents	1.1	1.1	0.0	0.0	460	460	0	0	409	409	0	0	99	40,442	8	9.3	88
Analgesics and Anesthetics	1.1	0.4	0.0	0.7	126	111	0	15	113	286	50	20	603	67,988	55	64.0	540
Neuromuscular Agents	1.8	0.5	0.2	1.1	143	72	33	37	78	140	165	34	799	62,637	42	48.8	438
Nutritional Products	0.8	0.1	0.0	0.7	12	0	0	12	16	4	0	17	199	3,260	27	31.4	263
Hematological Agents	1.6	0.3	0.1	1.1	57	45	1	10	36	132	9	9	451	16,164	28	32.6	283
Topical Products	0.8	0.3	0.1	0.5	44	28	3	13	52	87	49	27	451	23,413	50	58.1	532
Miscellaneous Products	0.1	0.1	0.0	0.1	3	2	0	0	21	37	0	4	10	207	7	8.1	75
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	7	0	0	0	26	0	0	0	23	607	9	10.5	83
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	7,363	544,870	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for Vermont, released by CMS in 00/2007. This table was produced on 04/10/2008.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 125 beneficiaries who were in nursing facilities for part of their enrollment and their 1,289 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

In Vermont, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND9 Nondual Beneficiaries

TABLE ND.10

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP-10 DRUG GROUP^{a, b, c, d}

NONDUAL BENEFICIARIES, VERMONT, 2004

			Users		Among Users			
		Number of	As a Percentage of All-Year Nursing Facility	Number of	Number of Rx per		Rx \$ per Benefit	
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Users	Residents	Benefit Months	Benefit Month	\$ per Rx	Month	
ANTIPSYCHOTICS	\$133,491	62	72.1 %	664	0.9	\$216	\$201	
ANALGESICS - Narcotic	57,331	51	59.3	505	0.8	141	114	
ANTICONVULSANT	51,544	41	47.7	440	1.2	95	117	
MISC PSYCHOTHERAPEUTIC AND								
NEUROLOGICAL	40,477	11	12.8	120	0.8	405	337	
ANTIDEPRESSANTS	37,499	66	76.7	703	1.0	54	53	
ULCER DRUGS	29,054	58	67.4	564	0.8	68	52	
DERMATOLOGICAL	20,142	100	116.3	1,136	0.3	51	18	
MISC. ENDOCRINE	20,261	8	9.3	86	0.8	281	236	
ANTIASTHMATIC	18,617	44	51.2	474	0.4	90	39	
ANTIHYPERLIPIDEMIC	10,573	13	15.1	141	0.8	100	75	
Total	418,989	454		4,833	n.a.	n.a.	n.a.	

Source: Data for this table are from the MAX 2004 file for Vermont, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 125 beneficiaries who were in nursing facilities for part of their enrollment and their 1,289 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST

AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}

NONDUAL BENEFICIARIES, VERMONT, 2004

	All Top 10 Drug	g Groups		ANTIPS	SYCHOTICS				ANALGESICS - Narcotic				
Beneficiary			Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months	Mean Number	Mean	Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months Among	Mean Number	Mean	
Characteristics	Number of Rx	Rx \$	Users	Residents	Users	of Rx	Rx \$	Users	Residents	Users	of Rx	Rx \$	
All	3,572	\$418,989	62	72.1 %	664	0.9	\$201	51	59.3 %	505	0.8	\$114	
Female	2,497	283,058	43	72.9	468	1.0	236	34	57.6	362	0.7	27	
Disabled	1,843	220,859	35	94.6	391	1.0	227	24	64.9	249	0.7	22	
0.4	1,803	216,235	34	97.1	386	1.0	228	22	62.9	243	0.7	22	
64 or younger	40	4,624	1	50.0	5	8.0	178	2	100.0	6	0.3	4	
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	
85 and older Other Eligibles	654	62,199	8	36.4	77	1.2	281	10	45.5	113	0.6	37	
•	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	
64 or younger	138	13,404	1	50.0	12	1.3	360	1	50.0	12	2.5	65	
65-74	201	17,062	2	22.2	18	1.8	299	5	55.6	55	0.2	1	
75-84	315	31,733	5	45.5	47	1.0	254	4	36.4	46	0.7	73	
85 and older	4.075	105.004	40	70.4	400	0.7	440	47	00.0	4.40		000	
Male	1,075	135,931	19	70.4	196	0.7	118	17	63.0	143	1.1	333	
Disabled	723	118,061	8	61.5	84	0.9	213	12	92.3	99	1.5	480	
64 or younger	723	118,061	8	61.5	84	0.9	213	12	92.3	99	1.5	480	
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	
Other Eligibles	352	17,870	11	78.6	112	0.6	46	5	35.7	44	0.4	3	
64 or younger	1	55	0	0.0	0	0.0	0	0	0.0	0	0.0	0	
65-74	176	8,894	5	125.0	51	0.2	6	0	0.0	0	0.0	0	
75-84	118	6,555	4	133.3	45	1.1	90	4	133.3	42	0.4	3	
85 and older	57	2,366	2	33.3	16	0.6	49	1	16.7	2	1.0	4	
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 125 beneficiaries who were in nursing facilities for part of their enrollment and their 1,289 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, VERMONT, 2004

		ANTICO	ONVULSANT			MISC PSYC	HOTHERAP	EUTIC AND I	NEUROLO	GICAL	ANTIDEPRESSANTS				
Beneficiary	Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months Among	Mean Number	Mean	Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months Among	Mean Number	Mean	Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months	Mean Number	Mean
Characteristics	Users	Residents	Users	of Rx	Rx \$	Users	Residents	Users	of Rx	Rx \$	Users	Residents	Users	of Rx	Rx \$
All	41	47.7 %	440	1.2	\$117	11	12.8 %	120	0.8	\$337	66	76.7 %	703	1.0	\$53
Female	28	47.5	303	1.2	105	10	16.9	111	0.8	352	41	69.5	445	1.0	58
Disabled	25	67.6	271	1.3	114	5	13.5	59	0.8	583	28	75.7	310	1.0	58
r	22	62.9	260	1.2	107	5	14.3	59	0.8	583	27	77.1	305	1.1	57
64 or younge	3	150.0	11	2.2	266	0	0.0	0	0.0	0		50.0	5	0.8	78
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	3	13.6	32	0.7	26	5	22.7	52	0.8	90	13	59.1	135	1.0	58
r	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younge	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	100.0	20	1.2	99
65-74	2	22.2	21	0.7	21	3	33.3	36	0.6	74	5	55.6	53	0.8	43
75-84	1	9.1	11	0.6	36	2	18.2	16	1.1	124	6	54.5	62	1.0	57
85 and older													_	_	
Male	13	48.1	137	1.3	145	1	3.7	9	1.1	156	25	92.6	258	0.9	46
Disabled	8	61.5	81	1.5	189	0	0.0	0	0.0	0	14	107.7	160	0.9	48
r 64 or younge	8	61.5	81	1.5	189	0	0.0	0	0.0	0	14	107.7	160	0.9	48
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	5	35.7	56	1.1	82	1	7.1	9	1.1	156	11	78.6	98	1.0	42
r 64 or younge	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	5	125.0	56	1.1	82	0	0.0	0	0.0	0	4	100.0	39	1.3	64
75-84	0	0.0	0	0.0	0	1	33.3	9	1.1	156	3	100.0	33	0.6	9
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	4	66.7	26	1.0	49
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for Vermont, released by CMS in 00/2007. This table was produced on 04/10/2008.

- a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 125 beneficiaries who were in nursing facilities for part of their enrollment and their 1,289 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit: \$ = Medicaid reimbursement.

TABLE ND.10C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, VERMONT, 2004

	ULCER DRUGS						DERMA	TOLOGICAL			MISC. ENDOCRINE				
Beneficiary Characteristics All	Number of Users 58	Users as % of All-Year Nursing Facility Residents 67.4 %	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$ \$52	Number of Users 100	Users as % of All-Year Nursing Facility Residents 116.3 %	Number of Benefit Months Among Users 1,136	Mean Number of Rx	Mean Rx \$ \$18	Number of Users 8	Users as % of All-Year Nursing Facility Residents 9.3 %	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$ \$236
Female	39	66.1	387	0.7	53	63	106.8	720	0.3	18	7	11.9	74	0.8	80
Disabled	25	67.6	259	0.6	48	43	116.2	504	0.4	21	3	8.1	36	1.0	113
r	23	65.7	253	0.6	48	43	122.9	504	0.4	21	3	8.6	36	1.0	113
64 or younge	2	100.0	6	0.8	56	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	14	63.6	128	1.0	62	20	90.9	216	0.2	11	4	18.2	38	0.7	48
r	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younge 65-74	2	100.0	20	1.1	111	5	250.0	52	0.2	10	0	0.0	0	0.0	0
75-84	3	33.3	34	1.0	45	4	44.4	46	0.1	1	0	0.0	0	0.0	0
75-64 85 and older	9	81.8	74	1.0	57	11	100.0	118	0.3	16	4	36.4	38	0.7	48
Male	19	70.4	177	0.8	49	37	137.0	416	0.4	18	1	3.7	12	1.0	1,198
Disabled	12	92.3	116	0.9	68	25	192.3	291	0.3	21	1	7.7	12	1.0	1,198
r	12	92.3	116	0.9	68	25	192.3	291	0.3	21	1	7.7	12	1.0	1,198
64 or younge	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	7	50.0	61	0.6	12	12	85.7	125	0.4	11	0	0.0	0	0.0	0
r	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younge	2	50.0	12	0.6	19	4	100.0	39	1.1	27	0	0.0	0	0.0	0
65-74 75-84	3	100.0	35	0.4	10	4	133.3	46	0.1	4	0	0.0	0	0.0	0
75-84 85 and older	2	33.3	14	0.9	8	4	66.7	40	0.2	3	0	0.0	0	0.0	0
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for Vermont, released by CMS in 00/2007. This table was produced on 04/10/2008.

- a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 125 beneficiaries who were in nursing facilities for part of their enrollment and their 1,289 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit: \$ = Medicaid reimbursement.

Table ND10C Nondual Beneficiaries

TABLE ND.10D CAID PHARMACY BENEFIT LISE AND REIMBURSEMENT PER BENEFI

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{6, b, c, d}
NONDUAL BENEFICIARIES, VERMONT, 2004

		ANTIA	STHMATIC			-	ANTIHYP	PERLIPIDEMI	С			
Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	All-Year Nursing \ Facility Residents	Benefit Months Among All- Year Nursing Facility Residents
All	44	51.2 %	474	0.4	\$39	13	15.1 %	141	0.8	\$75	86	838
Female	30	50.8	341	0.5	50	10	16.9	116	0.9	90	59	604
Disabled	20	54.1	225	0.6	55	6	16.2	70	8.0	61	37	390
	19	54.3	224	0.6	55	6	17.1	70	0.8	61	35	384
64 or younger	1	50.0	1	1.0	59	0	0.0	0	0.0	0	2	6
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older Other Eligibles	10	45.5	116	0.4	40	4	18.2	46	1.0	133	22	214
Other Liigibles	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
64 or younger	5	250.0	56	0.4	37	1	50.0	12	1.0	126	2	20
65-74	1	11.1	12	0.2	3	3	33.3	34	1.1	136	9	97
75-84	4	36.4	48	0.5	53	0	0.0	0	0.0	0	11	97
85 and older												
Male	14	51.9	133	0.2	12	3	11.1	25	0.1	6	27	234
Disabled	7	53.8	67	0.3	20	0	0.0	0	0.0	0	13	113
64 or vounger	7	53.8	67	0.3	20	0	0.0	0	0.0	0	13	113
64 or younger 65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older Other Eligibles	7	50.0	66	0.1	5	3	21.4	25	0.1	6	14	121
•	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	1
64 or younger	4	100.0	35	0.1	5	1	25.0	11	0.1	7	4	40
65-74	3	100.0	31	0.2	5	0	0.0	0	0.0	0	3	32
75-84	0	0.0	0	0.0	0	2	33.3	14	0.1	5	6	48
85 and older Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2004 file for Vermont, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 125 beneficiaries who were in nursing facilities for part of their enrollment and their 1,289 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.11

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}

VERMONT, 2004

	November	5							
	Number of	Percentage of Beneficiaries with at	Number of Part	Total Number Dr	ort D Evoluded			Part D Excluded Rx	
Beneficiary	at Least One Part	Least One Part D	D Excluded Rx	Part D	Rx \$ per	Total Part D		as a Percentage of	Total Number of
Characteristics	D Excluded Rx	Excluded Rx	per Beneficiary	Excluded Rx		Excluded Rx \$	Excluded Rx	All Nondual Rx \$	Beneficiaries
All	23,015	17.9 %	0.7	90,384	\$13	\$1,678,719	\$19	2.4 %	128,292
Age									
5 and younger	3,291	14.3	0.3	6,122	5	120,149	20	3.4	22,949
6-14	3,753	11.4	0.2	7,824	8	253,505	32	2.5	32,869
15-20	2,360	13.6	0.3	5,389	6	98,345	18	1.3	17,377
21-44	8,841	22.2	0.9	37,559	16	656,810	17	2.5	39,825
45-64	4,614	31.3	2.2	32,088	36	533,786	17	2.3	14,754
65-74	82	35.3	2.9	682	33	7,757	11	1.9	232
75-84	47	27.0	1.6	286	23	4,057	14	1.3	174
85 and older	27	24.1	3.9	434	38	4,310	10	3.2	112
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
Basis of Eligibility ^c									
Aged	100	26.7	2.7	996	31	11,578	12	2.0	374
Disabled	3,819	43.2	3.7	32,517	62	551,348	17	2.2	8,848
Adults	10,608	21.1	0.8	41,186	14	722,401	18	2.4	50,331
Children	8,469	12.3	0.2	15,623	6	392,065	25	2.5	68,664
Unknown	19	25.3	0.8	62	18	1,327	21	0.6	75
Gender									
Female	15,086	21.7	0.9	62,041	16	1,081,029	17	2.6	69,561
Male	7,929	13.5	0.5	28,343	10	597,690	21	2.1	58,731
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
Race									
White	15,968	22.4	1.0	71,042	18	1,309,453	18	2.5	71,133
African American	227	18.4	0.5	623	8	10,180	16	1.9	1,231
Other/unknown	6,820	12.2	0.3	18,719	6	359,086	19	2.0	55,928
Use of Nursing									
Facilities ^d									
Entire year	59	68.6	9.1	780	103	8,900	11	1.6	86
Part year	104	83.2	12.0	1,495	134	16,738	11	2.6	125
None	22,852	17.8	0.7	88,109	13	1,653,081	19	2.4	128,081
Maintenance									
Assistance Status	0.000	04.0		07.440		004.400	40	0.0	00.500
Cash	6,383	31.0	1.8	37,410	32	664,139	18	2.3	20,586
Medically needy	1,815	22.2	0.9	7,593	20	164,934	22	3.1	8,186
Poverty related	5,556	11.1	0.2	9,992	4	214,704	21	2.4	49,896
Other/unknown	9,261	18.7	0.7	35,389	13	634,942	18	2.2	49,624

Table ND11 Nondual Beneficiaries

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTICa,b VERMONT, 2004

Beneficiary Characteristics	Number Rx per Benefit Month	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Be Benefit Month	nzodiazepine \$ per Benefit Month	Number of Benefit Months
All	0.1	\$1	\$19	\$0	\$1	1,202,367
Age						
5 and younger	0.0	1	20	0	0	217,154
6-14	0.0	1	32	0	0	338,204
15-20	0.0	1	18	0	0	162,805
21-44	0.1	2	17	0	1	341,333
45-64	0.2	4	17	0	2	138,508
65-74	0.3	3	11	0	2	2,236
75-84	0.2	3	14	0	1	1,414
85 and older	0.6	6	10	0	1	713
Unknown	0.0	0	0	0	0	0
Basis of Eligibility ^c						
Aged	0.3	4	12	0	1	2,852
Disabled	0.3	6	17	0	3	98,177
Adults	0.1	2	18	0	1	426,521
Children	0.0	1	25	0	0	674,105
Unknown	0.1	2	21	0	0	712
Gender						
Female	0.1	2	17	0	1	660,758
Male	0.1	1	21	0	0	541,609
Unknown	0.0	0	0	0	0	0
Race						
White	0.1	2	18	0	1	688,081
African American	0.1	1	16	0	0	10,498
Other/unknown	0.0	1	19	0	0	503,788
Use of Nursing						
Facilities ^d				_		
Entire year	0.9	11	11	0	4	838
Part year	1.2	13	11	0	5	1,289
None	0.1	1	19	0	0	1,200,240
Maintenance Assistance Status						
Cash	0.2	3	18	0	1	216,190
Medically needy	0.1	2	22	0	1	72,273
Poverty related	0.0	0	21	0	0	478,900
Other/unknown	0.1	1	18	0	1	435,004

Table ND12 Nondual Beneficiaries

- a. Table ND.12 includes the beneficaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.13 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c} VERMONT, 2004

			Number Rx as a Percentage of All Part D				
Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Part D Excluded Rx \$	Total Number Rx.	\$ per Rx	Excluded Rx
All	28,204	\$60	\$1,678,719	100.0 %	90,384	\$19	100.0 %
Anorexia or weight loss/gain	85	303	25,729	1.5	261	99	0.3
Fertility drugs	3	109	327	0.0	7	47	0.0
Drugs for cosmetic purposes	132	13	1,674	0.1	177	9	0.2
Cough and cold medications	5,697	53	301,336	18.0	9,803	31	10.8
Vitamins and minerals	1,891	61	114,645	6.8	5,832	20	6.5
Non-prescription drugs	11,169	40	444,495	26.5	26,341	17	29.1
Barbiturates	136	55	7,462	0.4	1,210	6	1.3
Benzodiazepines	8,216	74	604,507	36.0	43,497	14	48.1
Other Part D Excl Rx Drugs	875	204	178,544	10.6	3,256	55	3.6

Source: Data for this table are from the MAX 2004 file for Vermont, released by CMS in 00/2007. This table was produced on 04/10/2008.

- b. Includes OTC drugs as well as prescription drugs.
- c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.13 includes the beneficaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2004. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

APPENDIX TABLE A.1 CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b} NONDUAL BENEFICIARIES, VERMONT, 2004

Beneficiary			Number of Ber	neficiaries				N	lumber of Ben	efit Months		
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	128,292	374	8,848	50,331	68,664	75	1,202,367	2,852	98,177	426,521	674,105	712
Age												
5 and younger	22,949	0	329	6	22,614	0	217,154	0	3,615	41	213,498	0
6-14	32,869	1	1,280	2	31,586	0	338,204	12	14,534	4	323,654	0
15-20	17,377	0	1,113	2,165	14,092	7	162,805	0	12,483	16,505	133,746	71
21-44	39,825	2	2,821	36,604	365	33	341,333	14	31,211	306,693	3,123	292
45-64	14,754	6	3,226	11,481	6	35	138,508	29	35,495	102,563	72	349
65-74	232	114	64	54	0	0	2,236	1,002	693	541	0	0
75-84	174	141	13	19	1	0	1,414	1,095	133	174	12	0
85 and older	112	110	2	0	0	0	713	700	13	0	0	0
Unknown	0	0	0	0	0	0		0	0	0	0	0
Gender												
Female	69,561	238	4,693	30,673	33,883	74	660,758	1,838	52,437	272,397	333,386	700
Male	58,731	136	4,155	19,658	34,781	1	0 541,609	1,014	45,740	154,124	340,719	12
Unknown	0	0	0	0	0	0	Ü	0	0	0	0	0
Race												
White	71,133	184	6,750	33,307	30,856	36	688,081	1,532	75,880	291,094	319,213	362
African American	1,231	4	83	529	615	0	0 10,498	22	847	4,018	5,611	0
Other/unknown	55,928	186	2,015	16,495	37,193	39	503,788	1,298	21,450	131,409	349,281	350
Use of Nursing Facilities ^c												
Entire year	86	36	50	0	0	0	838	335	503	0	0	0
Part year	125	12	93	19	0	1	1,289	108	970	199	0	12
None	128,081	326	8,705	50,312	68,664	74	1,200,240	2,409	96,704	426,322	674,105	700
Maintenance Assistance Status												
Cash	20,586	35	7,530	4,202	8,819	0	216,190	354	85,317	40,916	89,603	0
Medically needy	8,186	117	551	5,257	2,261	0	72,273	1,112	4,984	48,179	17,998	0
Poverty related	49,896	0	0	2,509	47,312	75	478,900	0	0	17,848	460,340	712
Other/unknown	49,624	222	767	38,363	10,272	0	435,004	1,386	7,876	319,578	106,164	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	128,292	374	8,848	50,331	68,664	75	1,202,367	2,852	98,177	426,521	674,105	712
FFS part year, with Rx claims	0	0	0	0	0	0		0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0		0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0		0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0		0	0	0	0	0

0

0

0

- a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2

MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a NONDUAL BENEFICIARIES, VERMONT, 2004

	Beneficiaries Benefit Months in Ce		Included in Cell K	of Table 1	Excluded from Cell	K of Table 1
		mber of Benefit Months		mber of Benefit Months		mber of Benefit Months
All	128,292	1,202,367	128,292	1,202,367	0	0
Fee-for-service (FFS) all year	128,292	1,202,367	128,292	1,202,367	0	0
FFS part year, with Rx claims	0	0	0	0	0	0
FFS part year, with no Rx claims	0	0	0	0	0	0
Managed care (MC) all year, with Rx claims	0	0	0	0	0	0
MC all year, with no Rx claims	0	0	0	0	0	0

Source: Data for this table are from the MAX 2004 file for Vermont, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.